Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.
Several other analysts have also recently weighed in on the stock. Guggenheim upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $355.00 to $403.00 in a report on Monday, September 23rd. Piper Jaffray Companies set a $435.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 8th. BMO Capital Markets set a $344.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, October 8th. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price objective on the stock in a report on Wednesday, August 7th. Finally, Canaccord Genuity decreased their price objective on shares of Regeneron Pharmaceuticals from $353.00 to $320.00 and set a “hold” rating on the stock in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $390.47.
Shares of Regeneron Pharmaceuticals stock traded up $2.07 during mid-day trading on Thursday, hitting $301.47. The stock had a trading volume of 216,165 shares, compared to its average volume of 772,342. The firm has a 50-day moving average of $287.84 and a two-hundred day moving average of $312.67. Regeneron Pharmaceuticals has a 12-month low of $271.37 and a 12-month high of $442.00. The company has a quick ratio of 3.11, a current ratio of 3.88 and a debt-to-equity ratio of 0.07. The firm has a market cap of $33.55 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 1.42 and a beta of 1.14.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Corporate insiders own 11.84% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,079,347 shares of the biopharmaceutical company’s stock worth $1,902,835,000 after buying an additional 54,247 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 2nd quarter. Invesco Ltd. now owns 1,344,273 shares of the biopharmaceutical company’s stock valued at $420,759,000 after purchasing an additional 46,055 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 2nd quarter. Northern Trust Corp now owns 978,518 shares of the biopharmaceutical company’s stock valued at $306,275,000 after purchasing an additional 5,530 shares in the last quarter. Parnassus Investments CA raised its holdings in shares of Regeneron Pharmaceuticals by 290.6% in the 2nd quarter. Parnassus Investments CA now owns 625,000 shares of the biopharmaceutical company’s stock valued at $195,625,000 after purchasing an additional 465,000 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 9.2% in the 2nd quarter. Pictet Asset Management Ltd. now owns 538,358 shares of the biopharmaceutical company’s stock valued at $168,506,000 after purchasing an additional 45,494 shares in the last quarter. Institutional investors own 66.55% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Stop Order Uses For Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.